Epigenomics AG (EPGNF)
USD 0.79
(0.0%)
USD 0.79
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 12.84 Million EUR | -18.97% |
| 2022 | 15.85 Million EUR | -35.73% |
| 2021 | 24.66 Million EUR | 262.85% |
| 2020 | 6.79 Million EUR | -51.41% |
| 2019 | 13.98 Million EUR | -35.91% |
| 2018 | 21.82 Million EUR | 10.39% |
| 2017 | 19.77 Million EUR | 8.51% |
| 2016 | 18.22 Million EUR | 44.64% |
| 2015 | 12.59 Million EUR | 11.29% |
| 2014 | 11.32 Million EUR | 2.16% |
| 2013 | 11.08 Million EUR | 61.11% |
| 2012 | 6.87 Million EUR | -64.66% |
| 2011 | 19.46 Million EUR | -42.48% |
| 2010 | 33.83 Million EUR | 106.91% |
| 2009 | 16.35 Million EUR | -19.37% |
| 2008 | 20.28 Million EUR | -11.48% |
| 2007 | 22.91 Million EUR | -23.96% |
| 2006 | 30.13 Million EUR | -33.03% |
| 2005 | 44.99 Million EUR | -15.55% |
| 2004 | 53.28 Million EUR | 70.2% |
| 2003 | 31.3 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 4.21 Million EUR | -61.94% |
| 2023 Q1 | 11.07 Million EUR | -30.11% |
| 2023 Q3 | 12.84 Million EUR | 204.59% |
| 2023 FY | 12.84 Million EUR | -18.97% |
| 2023 Q4 | 12.84 Million EUR | 0.0% |
| 2022 Q2 | 20.62 Million EUR | -8.1% |
| 2022 Q3 | 18.97 Million EUR | -8.0% |
| 2022 Q4 | 15.85 Million EUR | -16.44% |
| 2022 FY | 15.85 Million EUR | -35.73% |
| 2022 Q1 | 22.43 Million EUR | -9.02% |
| 2021 FY | 24.66 Million EUR | 262.85% |
| 2021 Q4 | 24.66 Million EUR | -8.69% |
| 2021 Q2 | 9.69 Million EUR | 2.01% |
| 2021 Q3 | 27.01 Million EUR | 178.75% |
| 2021 Q1 | 9.49 Million EUR | 39.75% |
| 2020 Q2 | 11.04 Million EUR | -18.52% |
| 2020 Q1 | 13.55 Million EUR | -3.13% |
| 2020 Q4 | 6.79 Million EUR | -23.02% |
| 2020 FY | 6.79 Million EUR | -51.41% |
| 2020 Q3 | 8.83 Million EUR | -20.03% |
| 2019 Q3 | 12.96 Million EUR | -16.62% |
| 2019 FY | 13.98 Million EUR | -35.91% |
| 2019 Q2 | 15.54 Million EUR | -16.67% |
| 2019 Q1 | 18.65 Million EUR | -14.52% |
| 2019 Q4 | 13.98 Million EUR | 7.91% |
| 2018 FY | 21.82 Million EUR | 10.39% |
| 2018 Q4 | 21.82 Million EUR | 74.78% |
| 2018 Q2 | 14.16 Million EUR | -15.15% |
| 2018 Q1 | 16.69 Million EUR | -15.57% |
| 2018 Q3 | 12.48 Million EUR | -11.85% |
| 2017 FY | 19.77 Million EUR | 8.51% |
| 2017 Q4 | 19.77 Million EUR | -11.66% |
| 2017 Q3 | 22.38 Million EUR | 74.24% |
| 2017 Q2 | 12.84 Million EUR | -16.27% |
| 2017 Q1 | 15.34 Million EUR | -15.8% |
| 2016 Q2 | 17.82 Million EUR | 38.64% |
| 2016 Q4 | 18.22 Million EUR | 46.9% |
| 2016 FY | 18.22 Million EUR | 44.64% |
| 2016 Q1 | 12.85 Million EUR | 2.05% |
| 2016 Q3 | 12.4 Million EUR | -30.4% |
| 2015 Q1 | 10.55 Million EUR | -6.8% |
| 2015 FY | 12.59 Million EUR | 11.29% |
| 2015 Q2 | 15.06 Million EUR | 42.79% |
| 2015 Q4 | 12.59 Million EUR | -11.63% |
| 2015 Q3 | 14.25 Million EUR | -5.36% |
| 2014 Q4 | 11.32 Million EUR | 45.2% |
| 2014 Q2 | 9.92 Million EUR | -13.44% |
| 2014 FY | 11.32 Million EUR | 2.16% |
| 2014 Q1 | 11.46 Million EUR | 3.5% |
| 2014 Q3 | 7.79 Million EUR | -21.47% |
| 2013 Q3 | 5.99 Million EUR | -16.9% |
| 2013 Q4 | 11.08 Million EUR | 84.84% |
| 2013 FY | 11.08 Million EUR | 61.11% |
| 2013 Q2 | 7.21 Million EUR | -21.36% |
| 2013 Q1 | 9.17 Million EUR | 33.38% |
| 2012 Q3 | 10.49 Million EUR | -23.65% |
| 2012 FY | 6.87 Million EUR | -64.66% |
| 2012 Q4 | 6.87 Million EUR | -34.49% |
| 2012 Q2 | 13.75 Million EUR | -16.91% |
| 2012 Q1 | 16.55 Million EUR | -14.97% |
| 2011 Q1 | 31.18 Million EUR | -7.85% |
| 2011 Q2 | 28.29 Million EUR | -9.27% |
| 2011 Q3 | 24.74 Million EUR | -12.53% |
| 2011 Q4 | 19.46 Million EUR | -21.35% |
| 2011 FY | 19.46 Million EUR | -42.48% |
| 2010 Q4 | 33.83 Million EUR | -9.47% |
| 2010 FY | 33.83 Million EUR | 106.91% |
| 2010 Q1 | 44.25 Million EUR | 170.61% |
| 2010 Q2 | 40.12 Million EUR | -9.34% |
| 2010 Q3 | 37.37 Million EUR | -6.84% |
| 2009 Q4 | 16.35 Million EUR | 0.0% |
| 2009 FY | 16.35 Million EUR | -19.37% |
| 2008 FY | 20.28 Million EUR | -11.48% |
| 2007 FY | 22.91 Million EUR | -23.96% |
| 2006 FY | 30.13 Million EUR | -33.03% |
| 2005 FY | 44.99 Million EUR | -15.55% |
| 2004 FY | 53.28 Million EUR | 70.2% |
| 2003 FY | 31.3 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| American Bio Medica Corporation | 1.26 Million USD | -912.182% |
| Arrayit Corporation | 1 Million USD | -1183.959% |
| Atlantic International Corp. | 4.43 Million USD | -189.53% |
| Biocept, Inc. | 30.87 Million USD | 58.395% |
| Bioqual, Inc. | 56.58 Million USD | 77.302% |
| CardioGenics Holdings Inc | 231.93 Thousand USD | -5438.084% |
| DermTech, Inc. | 121.93 Million USD | 89.466% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 4.18 Billion USD | 99.693% |
| HTG Molecular Diagnostics, Inc. | 17.77 Million USD | 27.749% |
| iMD Companies, Inc. | 190.13 Thousand USD | -6655.439% |
| IDenta Corp. | 1.52 Million USD | -739.914% |
| Interpace Biosciences, Inc. | 13.02 Million USD | 1.355% |
| Integrative Health Technologies, Inc. | 8.25 Million USD | -55.656% |
| InVitro International | 1.53 Million USD | -737.323% |
| Lumos Diagnostics Holdings Limited | 26.83 Million USD | 52.14% |
| Many Bright Ideas Technologies Inc. | 2312.00 USD | -555461.808% |
| Medical Imaging Corp. | 4.19 Million USD | -206.434% |
| NovelStem International Corp. | 2.25 Million USD | -469.72% |
| Optigenex Inc. | 1.88 Million USD | -580.223% |
| PharmChem, Inc. | 2.76 Million USD | -364.448% |
| Proteome Sciences plc | 14.58 Million USD | 11.939% |
| Response Genetics, Inc | 48.88 Million USD | 73.724% |
| Rennova Health, Inc. | 20.57 Million USD | 37.565% |
| RushNet, Inc. | 6.04 Million USD | -112.391% |
| ScreenPro Security Inc. | 1.26 Million USD | -918.314% |
| Stella Diagnostics Inc. | 472.42 Thousand USD | -2618.875% |
| StageZero Life Sciences Ltd. | 700.65 Thousand USD | -1733.234% |
| Todos Medical Ltd. | 15.26 Million USD | 15.867% |